Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Oct;28(4):415–420. doi: 10.1111/j.1365-2125.1989.tb03521.x

Lisinopril dose-response relationship in essential hypertension

H J Gomez, V J Cirillo, J A Sromovsky, E S Otterbein, W C Shaw, J E Rush, S G Chrysant, A H Gradman, A S Leon, E P MacCarthy, E B Nelson, J Pool, A Vedin
PMCID: PMC1379991  PMID: 2556172

Abstract

1 This was a multicentre, double-blind, parallel study in 216 patients with mild to moderate (supine diastolic blood pressure = 95-115 mm Hg) essential hypertension.

2 After a 4-week placebo washout, patients were randomized to placebo or lisinopril 1.25, 5, 20 or 80 mg once daily for 6 consecutive weeks. Supine and erect blood pressure was measured 24 h postdose at the end of weeks -2, 0, 2, 4, and 6.

3 There was a linear dose-response relationship for both supine and erect blood pressure. Diastolic blood pressure reductions in the lisinopril 20 and 80 mg day-1 groups were significantly greater than in the placebo or lisinopril 1.25 and 5 mg day-1 groups.

4 Lisinopril, at doses up to 80 mg day-1, was well tolerated.

Keywords: lisinopril, angiotensin converting enzyme inhibitor, hypertension, dose-response relationship

Full text

PDF
415

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergstrand R., Herlitz H., Johansson S., Berglund G., Vedin A., Wilhelmsson C., Gomez H. J., Cirillo V. J., Bolognese J. A. Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol. 1985 May;19(5):605–611. doi: 10.1111/j.1365-2125.1985.tb02687.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chalmers J. P., West M. J., Cyran J., De La Torre D., Englert M., Kramar M., Lewis G. R., Maranhao M. F., Myburgh D. P., Schuster P. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. J Cardiovasc Pharmacol. 1987;9 (Suppl 3):S89–S97. doi: 10.1097/00005344-198700003-00021. [DOI] [PubMed] [Google Scholar]
  3. Donohoe J. F., Laher M., Doyle G. D., Cooper W. D. Lisinopril in hypertension associated with renal impairment. J Cardiovasc Pharmacol. 1987;9 (Suppl 3):S66–S68. doi: 10.1097/00005344-198700003-00016. [DOI] [PubMed] [Google Scholar]
  4. Fyhrquist F., Grönhagen-Riska C., Tikkanen I., Junggren I. L. Long-term monotherapy with lisinopril in renovascular hypertension. J Cardiovasc Pharmacol. 1987;9 (Suppl 3):S61–S65. doi: 10.1097/00005344-198700003-00015. [DOI] [PubMed] [Google Scholar]
  5. Gomez H. J., Cirillo V. J., Moncloa F. The clinical pharmacology of lisinopril. J Cardiovasc Pharmacol. 1987;9 (Suppl 3):S27–S34. doi: 10.1097/00005344-198700003-00008. [DOI] [PubMed] [Google Scholar]
  6. Mörlin C., Baglivo H., Boeijinga J. K., Breckenridge A. M., Clement D., Johnston G. D., Klein W., Kramer R., Luccioni R., Meurer K. A. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. J Cardiovasc Pharmacol. 1987;9 (Suppl 3):S49–S52. [PubMed] [Google Scholar]
  7. Pool J. L., Gennari J., Goldstein R., Kochar M. S., Lewin A. J., Maxwell M. H., McChesney J. A., Mehta J., Nash D. T., Nelson E. B. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol. 1987;9 (Suppl 3):S36–S42. doi: 10.1097/00005344-198700003-00010. [DOI] [PubMed] [Google Scholar]
  8. Rush J. E., Merrill D. D. The safety and tolerability of lisinopril in clinical trials. J Cardiovasc Pharmacol. 1987;9 (Suppl 3):S99–107. doi: 10.1097/00005344-198700003-00023. [DOI] [PubMed] [Google Scholar]
  9. Schmidt R. Dose-finding studies in clinical drug development. Eur J Clin Pharmacol. 1988;34(1):15–19. doi: 10.1007/BF01061410. [DOI] [PubMed] [Google Scholar]
  10. Turri M., Stein G. The determination of practically useful doses of new drugs: some methodological considerations. Stat Med. 1986 Sep-Oct;5(5):449–457. doi: 10.1002/sim.4780050509. [DOI] [PubMed] [Google Scholar]
  11. Ulm E. H., Hichens M., Gomez H. J., Till A. E., Hand E., Vassil T. C., Biollaz J., Brunner H. R., Schelling J. L. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982 Sep;14(3):357–362. doi: 10.1111/j.1365-2125.1982.tb01991.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Zachariah P. K., Bonnet G., Chrysant S. G., DeBacker G., Goldstein R., Herrera J., Lindner A., Materson B. J., Maxwell M. H., McMahon F. G. Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. J Cardiovasc Pharmacol. 1987;9 (Suppl 3):S53–S58. doi: 10.1097/00005344-198700003-00013. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES